Annexon, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Douglas E. Love
- Full Time Employees
- 92
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1400 Sierra Point Parkway Brisbane CA United States of America 94005
- IPO Date
- Jul 24, 2020
- CIK
- 0001528115
- Website
- annexonbio.com
- Similar Companies
- Business
- Annexon, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing novel therapies targeting neuroinflammatory and autoimmune diseases via complement pathway inhibition. Founded in 2017 and headquartered in Brisbane, California, Annexon focuses on treating classical complement-mediated diseases affecting the brain, body, and eye. Its core product pipeline includes ANX005, an investigational monoclonal antibody in a pivotal Phase III trial for Guillain-Barré Syndrome; ANX007, an antigen-binding fragment in Phase III trials for geographic atrophy in dry age-related macular degeneration; ANX1502, an oral small molecule for autoimmune indications; and ANX009, a C1q-blocking fragment designed for subcutaneous delivery. The company develops and anticipates commercializing therapies primarily in the autoimmune, neurodegeneration, and ophthalmology sectors targeting rare, high-unmet medical needs. Its product candidates undergo late-stage clinical development with dosing modalities including intravenous, intravitreal, and oral administration. Annexon operates primarily in the United States but aims for regulatory approvals and commercialization potential in both the U.S. and Europe. Recent major developments include the initiation and ongoing enrollment of pivotal Phase III trials for ANX007 in geographic atrophy, planning head-to-head trials against market competitors such as SYFOVRE® (pegcetacoplan), and preparing for Biologics License Application filings for ANX005 based on clinical data anticipated by late 2024. In 2025, the company launched a $75 million public offering to support continued advancement of its neuroinflammatory treatment pipeline and expanded strategic investor interest through Nuveen LLC’s acquisition of a minority stake aligned with its high-yield resilience investment strategy. Annexon also plans to present focused R&D updates highlighting the therapeutic potential of its portfolio. Annexon sustains its business through strategic clinical program progression and investment support aimed at delivering transformative therapies for debilitating complement-driven diseases. This description summarizes Annexon's role as a clinical-stage biotechnology firm with a detailed focus on complement inhibition platforms and its recent financial and strategic developments in the last 1-2 years.
Company News
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon: Preserving Patient Function Is The Real Investment Opportunity
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon to Participate in Upcoming September Investor Conferences
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
Annexon Q2 Earnings Call Highlights
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
Annexon: Perfect Complement To A Speculative Biotech Portfolio
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
Annexon to Participate in Upcoming June Investor Conferences